Get the Stockscreener App
686.36
6.21%
-45.41
After Hours:
681.54
-4.82
-0.70%
Regeneron Pharmaceuticals Inc stock is traded at $686.36, with a volume of 1.83M.
It is down -6.21% in the last 24 hours and down -6.96% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$731.77
Open:
$705.11
24h Volume:
1.83M
Relative Volume:
2.60
Market Cap:
$71.96B
Revenue:
$14.34B
Net Income/Loss:
$4.50B
P/E Ratio:
16.51
EPS:
41.5626
Net Cash Flow:
$3.77B
1W Performance:
-8.07%
1M Performance:
-6.96%
6M Performance:
+5.12%
1Y Performance:
+20.64%
1-Day Range:
$668.85
$708.80
1-Week Range:
$668.85
$767.21
52-Week Range:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
686.36 | 76.72B | 14.34B | 4.50B | 3.77B | 41.56 |
VRTX
Vertex Pharmaceuticals Inc
|
423.24 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
ARGX
Argen X Se Adr
|
776.02 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.19 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
290.80 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-31-26 | Resumed | Piper Sandler | Overweight |
| Mar-06-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-03-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-24-25 | Initiated | HSBC Securities | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-14-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-30-25 | Downgrade | Argus | Buy → Hold |
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Regeneron Pharmaceuticals (REGN) Margins Hold Near 31% Challenging Bearish Profitability Narratives - simplywall.st
Truist cuts Regeneron stock price target on FDA approval delay By Investing.com - Investing.com Canada
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Plans $0.94 Quarterly Dividend - MarketBeat
Regeneron Stock Tumbles on Earnings. Upcoming Data Matter More for the Stock. - Barron's
Regeneron Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat
Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Regeneron Pharmaceuticals (NASDAQ:REGN) Announces Quarterly Earnings Results - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Trading Down 7.8%Here's What Happened - MarketBeat
Regeneron Pharmaceuticals Delivers 19% Revenue Growth in Q1 2026 - AlphaStreet
Regeneron Pharmaceuticals Inc Stock (REGN) Moved Down by 7.82% on Apr 29: Facts Behind the Movement - TradingKey
Regeneron Flags FDA Delays For Eylea HD Prefilled Syringe - Benzinga
Regeneron Pharmaceuticals Releases Q1 2026 Financial Results - AlphaStreet
Regeneron shares fall 5% on Eylea sales decline, regulatory delays By Investing.com - Investing.com Canada
Raymond James cuts Regeneron stock price target on Eylea HD miss - Investing.com Canada
Regeneron Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Oil Surges 6%, S&P 500 Wobbles Before Fed And Tech Earnings: Stock Market Today - Benzinga
Regeneron beats quarterly estimates on Dupixent demand; shares fall on Eylea weakness - Reuters
Intel, NXP Semiconductors, Seagate, Bloom Energy, Avis, Regeneron, Robinhood, and More Stock Movers - Barron's
Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength - Yahoo Finance
Regeneron Pharmaceuticals, Inc. announces an Equity Buyback for $3,000 million worth of its shares. - marketscreener.com
Tranche Update on Regeneron Pharmaceuticals, Inc.'s Equity Buyback Plan announced on February 4, 2025. - marketscreener.com
Regeneron basks in first gene therapy approval as Dupixent, Eylea carry robust Q1 earnings - BioSpace
Regeneron Pharmaceuticals: Q1 Beat Driven By Dupixent And Eylea HD Strength (NASDAQ:REGN) - Seeking Alpha
Earnings call transcript: Regeneron Q1 2026 beats estimates, stock dips - Investing.com
Regeneron drops despite Q1 beat, $3B share buyback program - MSN
Regeneron shares slide despite Q1 beat - Yahoo! Finance Canada
Regeneron beats quarterly estimates on strong Dupixent demand - WHTC
Regeneron Pharmaceuticals (REGN) Reports Strong Q1 2026 Earnings and Announces $3B Buyback - GuruFocus
Is Regeneron (REGN) Still 23.3% Undervalued After Q1 2026? Non-G - GuruFocus
Regeneron Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:REGN) 2026-04-29 - Seeking Alpha
Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo! Finance Canada
Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock - TechStock²
Regeneron stock drops despite Q1 beat (REGN:NASDAQ) - Seeking Alpha
Regeneron Tops Q1 Estimates on Dupixent Momentum - Yahoo Finance
Regeneron (REGN) Reports Strong Q1 Revenue and New Drug Pricing Initiative - GuruFocus
Regeneron (REGN) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance Australia
Regeneron beats quarterly results estimates on strong Dupixent demand - Yahoo Finance
Regeneron Pharmaceuticals Q1 Adjusted Earnings, Revenue Rise - marketscreener.com
Regeneron beats first quarter estimates on Dupixent strength By Investing.com - Investing.com Nigeria
REGENERON PHARMACEUTICALS ($REGN) Releases Q1 2026 Earnings - Quiver Quantitative
Mitsubishi UFJ Trust & Banking Corp Decreases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Reports First Quarter 2026 Financial and Operating Results - The Manila Times
Regeneron (NASDAQ:REGN) Reports Strong Q1 CY2026 - Yahoo Finance
Regeneron: Q1 Earnings Snapshot - KTVB
Certuity LLC Reduces Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron strikes deal with Trump administration to cut drug prices - MSN
Is It Too Late To Consider Regeneron (REGN) After Its 29% One-Year Rally? - Yahoo Finance
Hemophilia B Pipeline Set for Transformational Breakthroughs - openPR.com
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
How Will Regeneron Pharmaceuticals Stock React To Its Upcoming Earnings? - Trefis
Kiniksa posts Q1 beat thanks to Regeneron drug (KNSA:NASDAQ) - Seeking Alpha
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.13%
0.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):